Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exenatide in Parkinson's Disease
NCT03456687Phase 1Completed
- Sponsor
- University of Florida
- Start
- Jun 2018
- Primary completion
- Oct 2020
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of exenatide in Parkinson's disease (PD), sponsored by University of Florida. Primary endpoints: Change in free-water accumulation in the substantia nigra at 1 year, Change in blood oxygen level-dependent (BOLD) signal in the posterior putamen at 1 year and 2 more. Started Jun 2018; status: completed.
02
Drugs
exenatide
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT03456687.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03456687.